ArticleBritish journal of haematology2025
Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis.
Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evolution of therapeutic paradigms in Hodgkin lymphoma: from "cure-oriented" to "functional cure".Frontiers in oncology · 2026Review
- Classical Hodgkin Lymphoma Today.Mediterranean journal of hematology and infectious diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Eighty-two patients were eligible for allogeneic transplantation (Allo-SCT) at our Institution between April 2014 and August 2022. Of these, 72 actually received Allo-SCT, n = 44 after checkpoint inhibitor (CPI) containing salvage therapy (CPI cohort) and n = 28 with brentuximab-vedotin (BV) containing therapy without CPI (BV cohort). With a median follow-up of 63 months, the CPI cohort had improved cumulative incidence of relapse (5% vs. 37%, p = 0.002) and progression-free survival (PFS) (79% and 56%, p = 0.049) relative to the BV group. By multivariable analysis, pretransplant CPI resulted in the only independent predictor of relapse (hazard ratio [HR]: 0.124, 95% confidence interval 0.270-0.570, p = 0.007) and a strong predictor for PFS (HR 0.43, 95% CI 0.18-1.02, p = 0.057). Our findings support the use of CPI over BV as the first-line salvage therapy for R/R HL patients relapsing after autologous stem cell transplantation when consolidation with Allo-SCT is planned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.